Dribin, T. E., Sampson, H. A., Zhang, Y., Boyd, S., Zhang, N., Michelson, K. A., Neuman, M. I., Brousseau, D. C., Mistry, R. D., Freedman, S. B., Aronson, P. L., Bergmann, K. R., Boswell, B., Chinta, S. S., Chua, W.-J., Cohen, A. R., Cohen, J. S., Daggett, A., Davis, J. R., … Woolf, S. (2025). Timing of repeat epinephrine to inform paediatric anaphylaxis observation periods: a retrospective cohort study. The Lancet Child & Adolescent Health, 9(7), 484–496. https://doi.org/10.1016/s2352-4642(25)00139-7

Dave, C. V., Brittenham, G. M., Carson, J. L., & Setoguchi, S. (2022). Risks for Anaphylaxis With Intravenous Iron Formulations. Annals of Internal Medicine, 175(11), W143–W144. https://doi.org/10.7326/l22-0283

Li, X., Ostropolets, A., Makadia, R., Shoaibi, A., Rao, G., Sena, A. G., Martinez-Hernandez, E., Delmestri, A., Verhamme, K., Rijnbeek, P. R., Duarte-Salles, T., Suchard, M. A., Ryan, P. B., Hripcsak, G., & Prieto-Alhambra, D. (2021). Characterising the background incidence rates of adverse events of special interest for covid-19 vaccines in eight countries: multinational network cohort study. BMJ, n1435. https://doi.org/10.1136/bmj.n1435

Dave, C. V., Brittenham, G. M., Carson, J. L., & Setoguchi, S. (2022). Risks for Anaphylaxis With Intravenous Iron Formulations. Annals of Internal Medicine, 175(5), 656–664. https://doi.org/10.7326/m21-4009